recurrent breast cancer
Original Article Comparative analysis between multimodalities for refractory locoregional recurrent breast cancer
... the recurrent lesions and reduce the potential risk of systemic ...systemic recurrent lesions can be fully controlled, surgery or radiotherapy should be selected to eliminate the remnant topical ...wall ...
7
Changes in the ER, PgR, HER2, p53 and Ki 67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis
... This biological change is due to the progression of cancer and metastasis. The authors in most studies [3-5] have stated that hormone receptors (HRs) change read- ily while there are few changes in HER2. ...
7
Original Article Comparison of microRNA expression levels between primary and recurrent breast cancer: microRNA-133a, microRNA-191, and microRNA-204 can predict local recurrence of breast cancer
... primary breast cancers and 5 corresponding recurrent breast cancers, we evaluated the expression of 158 miRNAs using PANArray miRNA expression pro- filing system (Panagene, Korea) according to the ...
10
A case of HER 2 positive recurrent breast cancer showing a clinically complete response to trastuzumab containing chemotherapy after primary treatment of triple negative breast cancer
... of recurrent breast cancer is less clear ...with recurrent breast ...advanced breast cancer ...with recurrent breast ...triple-negative breast ...
5
Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
... Elevated serum HER2 levels are associated with HER2 over- expression and amplification in breast cancer tissue. Never- theless, discordant results between serum and tissue can be obtained in a small subset ...
8
EuropePMC-PMC5540165.pdf
... locally recurrent breast cancer, but the competing medical conditions that are more likely to impact survival, similar to other treatment and screening ...older breast cancer survivors ...
16
Re-irradiation for locally recurrent refractory breast cancer
... the breast/chest wall +/- regional lymph ...confirmed recurrent breast cancer and had been previously treated with radiation to the breast/chest wall and were retreated to the same ...
12
Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study
... Approval was obtained from independent ethics committees and regulatory authorities (US Oncology, Inc. Institutional Review Board; Western Institutional Review Board; Medical University of South Carolina, Office of ...
9
Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway
... complex cancer biomarkers was further discussed by Anne-Lise Børresen-Dale, Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital The Norwegian Radiumhospital, Oslo, ...
15
Successful Treatment of Recurrent Triple Negative Breast Cancer with Combination of Targeted Therapies
... triple-negative breast can- cer, who developed diffuse liver metastases following lumpectomy and combination chemotherapy with docetaxel, dox- orubicin and cyclophosphamide, re-excision and radiation ...negative ...
5
Genetic risk variants associated with in situ breast cancer
... BC: breast cancer; BCAC: Breast Cancer Association Consortium; BCIS: breast cancer in situ; BMI: body mass index; BPC3: National Cancer Institute ’ s Breast and ...
10
Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.
... Australian Breast Cancer Family Study; ABCS, Amsterdam Breast Cancer Study; BBCC, Bavarian Breast Cancer Cases and Controls; BBCS, British Breast Cancer Study; ...
25
Comparative Oncogenomics Implicates the Neurofibromin 1 Gene (NF1) as a Breast Cancer Driver
... human breast tumors (Hanahan and Weinberg 2011), Chaos3 tumors had high levels of aneuploidy and drastic variation in chro- mosome number, even within the cells of a single tumor (Figure ...highly recurrent ...
25
Abstract: Breast cancer is the most common cancer in women and distant site metastasis is the
... in cancer metastases and they are regulated by epigenetic mechanisms ...invasive breast cancer tissues [98,102–104]. miR-9 promotes breast cancer progression through targeting CHD1, the ...
18
Systems biology analysis reveals NFAT5 as a novel biomarker and master regulator of inflammatory breast cancer
... of cancer such as lymphocytic leukemia and lung cancer are beginning to emerge through extensive molecular profiling studies ...to Cancer (145 ...
13
Angiogenesis inhibitors in the treatment of prostate cancer
... Thalidomide has also been tested in combination with chemotherapy in several phase II studies. In a rando- mized phase II study, 75 patients with metastatic cas- trate resistant prostate cancer received weekly ...
12
Association of host immunity with Helicobacter pylori infection in recurrent gastric cancer
... H. pylori infection usually induces a strong T helper 1 (Th1) inflammatory response, which is characterized by cellular infiltration induced by cytokine and chemokine secretion. During the pathogenesis from chronic ...
5
Plasma 25-Hydroxy Vitamin-D and Risk of Breast Cancer: A Case Control Study
... reduce cancer mortality through its effects on incidence and/or survival (Govannucci, ...reduce cancer incidence and promote survival including suppressing tumor progression by reducing cell proliferation ...
8
Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer
... intravenous infusion on days 1 and 8 of a 21-day cycle and compared with TPC, defined as a single-agent chemotherapy, hormonal therapy, or biological therapy approved for the treat- ment of cancer and administered ...
8
Radiotherapy and Hyperthermia in the Treatment of Locoregional Recurrent Cancer-Report of the First Patients Treated in Portugal
... Similarly to other cancer treatments, the tolerance of normal tissues to HT is also variable and different disease locations require specific thermic doses. The central nervous system tissues are particularly ...
5